As of Feb 12
| +0.18 / +0.37%|
The 33 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 59.22, with a high estimate of 74.77 and a low estimate of 44.42. The median estimate represents a +21.35% increase from the last price of 48.80.
The current consensus among 33 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.